Department of Pharmacy, University College of Pharmaceutical Sciences, Kakatiya University, Warangal, India.
Pharm Dev Technol. 2013 Sep-Oct;18(5):1230-7. doi: 10.3109/10837450.2012.660698. Epub 2012 Feb 21.
The objective of this investigation was to develop the cefuroxime axetil sustained-release floating tablets to prolong the gastric residence time and compare their pharmacokinetic behavior with marketed conventional tablets (Zocef). The floating tablets were developed using polymers like HPMC K4M and HPMC K100M alone, and polymer combination of HPMC K4M and Polyox WSR 303 by effervescent technique. Tablets were prepared by slugging method and evaluated for their physical characteristics, in vitro drug release, and buoyancy lag time. The best formulation (F10) was selected based on in vitro characteristics and used in vivo radiographic and bioavailability studies in healthy human volunteers. All the formulations could sustain drug release for 12 h. The dissolution profiles were subjected to various kinetic release models and it was found that the mechanism of drug release followed Peppas model. The in vivo radiographic studies revealed that the tablets remained in stomach for 225 ± 30 min. Based on in vivo performance, the developed floating tablets showed superior bioavailability than Zocef tablet. Based on in vivo performance significant difference was observed between Cmax, tmax, t1/2, AUC0-∞, and mean residence time of test and reference (p<0.05). The increase in relative bioavailability of test was 1.61 fold when compared to reference.
本研究旨在开发头孢呋辛醋乙酯缓释漂浮片,以延长胃内滞留时间,并将其药代动力学行为与市售普通片剂(Zocef)进行比较。采用 HPMC K4M 和 HPMC K100M 等聚合物,以及 HPMC K4M 和聚氧乙烯 WSR 303 的聚合物组合,通过泡腾技术开发了漂浮片。采用冲压法制备片剂,并对其物理特性、体外药物释放和漂浮滞后时间进行评价。根据体外特性选择最佳配方(F10),并在健康人体志愿者中进行体内放射照相和生物利用度研究。所有配方均可持续释放药物 12 小时。对溶出曲线进行了各种动力学释放模型的分析,结果表明药物释放机制符合 Peppas 模型。体内放射照相研究表明,片剂在胃中停留时间为 225±30 分钟。根据体内性能,开发的漂浮片显示出比 Zocef 片剂更高的生物利用度。与参比制剂相比,受试制剂的 Cmax、tmax、t1/2、AUC0-∞和平均滞留时间的体内性能存在显著差异(p<0.05)。与参比制剂相比,受试制剂的相对生物利用度增加了 1.61 倍。